Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.1
3.7
Journals
Pathogens
Special Issues
Novel Vaccine Strategies against Intracellular Bacteria
share announcement

Novel Vaccine Strategies against Intracellular Bacteria

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Vaccines and Therapeutic Developments".

Deadline for manuscript submissions: closed (20 January 2022) | Viewed by 6855

Special Issue Editor

Prof. Dr. Lisa A. Morici

E-Mail Website
Guest Editor
Tulane University School of Medicine, New Orleans, LA 70112, USA
Interests: vaccines; adjuvants; outer membrane vesicles; bacteria

Special Issue Information

Dear Colleagues,

Vaccine platforms that are effective against intracellular bacterial pathogens remain a high priority. In addition to the global impact of intracellular bacterial infections on public health, the alarming increase in multidrug resistant strains such as Mycobacterium tuberculosis and Salmonella spp., and the potential threat of biological misuse with select agents, such as Francisella tularensis and Burkholderia pseudomallei, highlight the urgent need for safe and effective vaccines against this collective group of pathogens. A vaccine that can elicit a range of immune responses, including antibody, helper CD4+ and cytotoxic CD8+ T cells may be especially desirable for many bacteria that establish intracellular infection. This issue welcomes vaccine research studies that encompasses novel approaches to prevent intracellular bacterial infection. In particular, innovative platforms, adjuvants, and delivery systems that can elicit a wide range of immune responses, including tissue-resident memory responses, are sought after and encouraged.

Prof. Dr. Lisa A. Morici
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • adjuvants
  • delivery systems
  • infection
  • antibody
  • cellular immunity

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2419 KiB  
Article
An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection
by Jaikin E. Harrell, Jonathan R. Kurtz, David L. Bauer, J. Timothy Prior, Patrick S. Gellings, Lisa A. Morici and James B. McLachlan
Pathogens 2021, 10(5), 616; https://0-doi-org.brum.beds.ac.uk/10.3390/pathogens10050616 - 18 May 2021
Cited by 3 | Viewed by 3301
Abstract
Non-typhoidal salmonellosis, caused by Salmonella enterica serovar Typhimurium is a common fecal-oral disease characterized by mild gastrointestinal distress resulting in diarrhea, chills, fever, abdominal cramps, head and body aches, nausea, and vomiting. Increasing incidences of antibiotic resistant invasive non-typhoidal Salmonella infections makes this [...] Read more.
Non-typhoidal salmonellosis, caused by Salmonella enterica serovar Typhimurium is a common fecal-oral disease characterized by mild gastrointestinal distress resulting in diarrhea, chills, fever, abdominal cramps, head and body aches, nausea, and vomiting. Increasing incidences of antibiotic resistant invasive non-typhoidal Salmonella infections makes this a global threat requiring novel treatment strategies including next-generation vaccines. The goal of the current study was to formulate a novel vaccine platform against Salmonella infection that could be delivered orally. To accomplish this, we created a Salmonella-specific vaccine adjuvanted with Burkholderia pseudomallei outer membrane vesicles (OMVs). We show that adding OMVs to a heat-killed oral Salmonella vaccine (HKST + OMVs) protects against a lethal, oral challenge with Salmonella. Further, we show that opsonizing anti-Salmonella antibodies are induced in response to immunization and that CD4 T cells and B cells can be induced when OMVs are used as the oral adjuvant. This study represents a novel oral vaccine approach to combatting the increasing problem of invasive Salmonella infections. Full article
(This article belongs to the Special Issue Novel Vaccine Strategies against Intracellular Bacteria)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 430 KiB  
Review
Recent Progress in Shigella and Burkholderia pseudomallei Vaccines
by Itziar Chapartegui-González, Sarah Bowser, Alfredo G. Torres and Nittaya Khakhum
Pathogens 2021, 10(11), 1353; https://0-doi-org.brum.beds.ac.uk/10.3390/pathogens10111353 - 20 Oct 2021
Cited by 3 | Viewed by 3018
Abstract
Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary [...] Read more.
Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria Shigella and Burkholderia pseudomallei, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials. Full article
(This article belongs to the Special Issue Novel Vaccine Strategies against Intracellular Bacteria)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop